title: 125I Brachytherapy in Locally Advanced Nonsmall Cell Lung Cancer After Progression of Concurrent Radiochemotherapy.
abstract: To investigate the safety and effectiveness of computed tomography (CT)-guided I seed implantation for locally advanced nonsmall cell lung cancer (NSCLC) after progression of concurrent radiochemotherapy (CCRT).We reviewed 78 locally advanced NSCLC patients who had each one cycle of first-line CCRT but had progressive disease identified from January 2006 to February 2015 at our institution. A total of 37 patients with 44 lesions received CT-guided percutaneous I seed implantation and second-line chemotherapy (group A), while 41 with 41 lesions received second-line chemotherapy (group B).Patients in group A and B received a total of 37 and 41 first cycle of CCRT treatment. The median follow-up was 19 (range 3-36) months. After the second treatment, the total response rate (RR) in tumor response accounted for 63.6% in group A, which was significantly higher than that of group B (41.5%) (P = 0.033). The median progression-free survival time (PFST) was 8.00 ± 1.09 months and 5.00 ± 0.64 months in groups A and B (P = 0.011). The 1-, 2-, and 3-year overall survival (OS) rates for group A were 56.8%, 16.2%, and 2.7%, respectively. For group B, OS rates were 36.6%, 9.8%, and 2.4%, respectively. The median OS time was 14.00 ± 1.82 months and 10.00 ± 1.37 months for groups A and B, respectively (P = 0.059). Similar toxicity reactions were found in both groups. Tumor-related clinical symptoms were significantly reduced and the patients' quality of life was obviously improved.CT-guided I seed implantation proved to be potentially beneficial in treating localized advanced NSCLC; it achieved good local control rates and relieved clinical symptoms without increasing side effects.
authors.affiliation: From the State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center (ZX, GL, JH, ZZ, LS, CL, FZ), and Guangzhou Women and Children Health Care Center, Guangzhou, China (ZL).
authors.forename: Zhanwang
authors.initials: Z
authors.lastname: Xiang
authors.forename: Guohong
authors.initials: G
authors.lastname: Li
authors.forename: Zhenyin
authors.initials: Z
authors.lastname: Liu
authors.forename: Jinhua
authors.initials: J
authors.lastname: Huang
authors.forename: Zhihui
authors.initials: Z
authors.lastname: Zhong
authors.forename: Lin
authors.initials: L
authors.lastname: Sun
authors.forename: Chuanxing
authors.initials: C
authors.lastname: Li
authors.forename: Funjun
authors.initials: F
authors.lastname: Zhang
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001918:Brachytherapy / Q000379:methods*; D002289:Carcinoma, Non-Small-Cell Lung / Q000401:mortality / Q000532:radiotherapy* / Q000628:therapy; D059248:Chemoradiotherapy; D002648:Child; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D007457:Iodine Radioisotopes; D008175:Lung Neoplasms / Q000401:mortality / Q000532:radiotherapy* / Q000628:therapy; D008297:Male; D008875:Middle Aged; D011788:Quality of Life; D015641:Radiography, Interventional; D055815:Young Adult
chemical_list: D007457:Iodine Radioisotopes